Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-10-01 | Anne M. VanLent, age 65, has served as a member of our Board of Directors since May 2013. ... Ms. VanLent’s extensive leadership and finance experience, and her extensive experience serving as a board member, audit committee member and audit committee chair of public companies in the life sciences industry led to the conclusion that he should serve on the Company’s Board of Directors. ... Audit Committee Chair. ... Nominating and Corporate Governance Committee Member. ... Director Compensation Table shows total compensation of $72,304. |
| 2014-10-03 | Anne M. VanLent, age 66, has served as a member of the Company’s Board of Directors since May 2013. Ms. VanLent is currently President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. |
| 2015-09-30 | The members of the Company’s Audit Committee are Ms. VanLent (Chair), Mr. Dougherty and Mr. Richard. The Nominating and Governance Committee are Dr. Cox (Chair), Mr. Richard, and Ms. VanLent. |
| 2016-09-27 | Anne M. VanLent, age 68, has served as a member of the Company’s Board of Directors since May 2013, as Lead Independent Director since November 2015, and as Chair of the Audit Committee since May 2013. ... Ms. VanLent’s extensive leadership and finance experience, and her extensive experience serving as a board member, audit committee member and audit committee chair of numerous public companies in the life sciences industry, led to the conclusion that she should serve on the Company’s Board of Directors. |
| 2018-02-26 | Anne M. VanLent has served as a member of the board of directors since 2013. For fiscal 2018, she serves as Chair of the Audit Committee and on the Compensation Committee. Director Compensation 2017: $80,065. |
| 2019-03-11 | Anne M. VanLent has served as a member of our board of directors since 2013. Ms. VanLent is President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. |
Data sourced from SEC filings. Last updated: 2025-06-24